
|Videos|July 19, 2017
Treatment of ALK+ Non-Small Cell Lung Cancer
Treatment of ALK+ Non-Small Cell Lung Cancer
Advertisement
- A 62-year-old female never-smoker presented with dyspnea, cough and fatigue.
- Patient has a performance status of 1 due to the decrease in her daily activities.
- Chest X-ray showed multiple bilateral lung nodules.
- PET/CT showed left adrenal metastases.
- Brain MRI was negative.
- Bronchoscopy was performed with a fine needle aspirate biopsy.
- Pathology results showed moderately differentiated adenocarcinoma.
- Molecular testing showed ALK-rearrangement.
- Patient was started on ceritinib.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5







































